Holen Sie sich die Stockscreener-App
27.61
0.67%
-0.175
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$27.79
Offen:
$27.76
24-Stunden-Volumen:
1.91M
Relative Volume:
0.05
Marktkapitalisierung:
$157.62B
Einnahmen:
$63.32B
Nettoeinkommen (Verlust:
$7.52B
KGV:
21.17
EPS:
1.3043
Netto-Cashflow:
$9.48B
1W Leistung:
-4.88%
1M Leistung:
+3.16%
6M Leistung:
+2.97%
1J Leistung:
+11.72%
1-Tages-Spanne:
$27.57
$27.79
1-Wochen-Bereich:
$27.57
$29.21
52-Wochen-Spanne:
$23.58
$29.21
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.66 | 158.39B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,132.96 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
268.77 | 648.55B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
248.93 | 439.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.73 | 366.28B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
138.82 | 261.73B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Hochstufung | Argus | Hold → Buy |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2026-02-20 | Eingeleitet | Barclays | Underweight |
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Novartis India to Acquire Pfizer’s BP Drug Brands for ₹1,250 Crore - Chemical Industry Digest
Mandi Rollerson Takes on New AI Change and Adoption Leadership Role at Pfizer - hrtoday.in
Why Pfizer Stock Was so Healthy in August - Yahoo Finance
Inside Pfizer’s Fight Against Counterfeit Medicine - Pfizer
Why Pfizer Stock Was so Healthy in August - The Motley Fool
Why Is Pfizer (NYSE:PFE) Trading At Such A Wide Discount To Its Healthcare Peers? - kalkinemedia.com
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - Business Wire
💊 Pfizer to discontinue Minipress XL in India 🤝 Novartis India buys the brand for ₹1,250 crore 📉 But Pfizer India gets just ₹131 crore of the deal Ekta Batra #Pfizer #Novartis #MinipressXL #PfizerIndia #NovartisIndia #CNBCTV18Digital - LinkedIn
Precision Trading with Pfizer Inc. (PFE) Risk Zones - Stock Traders Daily
Novartis India acquires Pfizer brands for $132m - Yahoo Finance
Pfizer shares hit 52-week low after Minipress XL discontinuation; Novartis zooms 13% - Business Today
Novartis India to Acquire Minipress, Minipres Trademarks From Pfizer for Rs 1,250 Crore - Medical Dialogues
Pfizer to Discontinue Minipress XL in India, Receives USD 13.9 Mn From US Parent - Medical Dialogues
Pfizer stock heads into the open after a flat close - AD HOC NEWS
Pfizer (PFE) Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now - Yahoo Finance
Maharashtra: Novartis India buys Minipress brands from Pfizer for Rs 1250 crore - Deccan Chronicle
This Is What I'd Do With Pfizer Stock Right Now - The Globe and Mail
Novartis India to Acquire Pfizer’s Minipress Trademarks for Rs 1,250 Crore - ChemAnalyst
Novartis India Ltd to acquire BP drug trademarks from Pfizer Inc, for ₹1,250 crore - BusinessLine
ChrysCap-controlled Novartis India to buy Pfizer’s blood pressure brand Minipress - VCCircle
Novartis India buys Minipress brands from Pfizer for ₹1,250 crore - Business Standard
Novartis India to acquire Pfizer's 'Minipress' trademark for ₹1,250 crore - ET Manufacturing
Novartis India to Buy Pfizer’s Minipress Brand for Rs 1,250 Cr - Equitypandit
Pfizer Inc. stock gains on Minipress XL exit and solid Q2 2026 figures - AD HOC NEWS
Novartis India to acquire Minipress, Minipres Trademarks from Pfizer for Rs 1,250 crore - Business Upturn
Novartis India: Why Is the Pharma Stock Spending ₹1,250 Crore to Acquire Pfizer’s Minipress Brand? - Trade Brains
Pfizer, Inc. (PFE) Stock Analysis: Evaluating the 6.05% Dividend Yield and Its Implications for Investors - DirectorsTalk Interviews
Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks - latestly.com
Pfizer to Receive Rs 131.38 Crore After Minipress XL Discontinuation; Know Details - Dalal Street Investment Journal
Novartis India to acquire Pfizer trademarks 'Minipress' and 'Minipres' for Rs 1,250 crore - Mid-Day
Novartis India buys Minipress, Minipres rights from Pfizer for ₹1,250cr - NewsBytes
Novartis India Buys Minipress From Pfizer For ₹1,250 Crore - Whalesbook
Minipress changes hands: Novartis India buys Pfizer brands for Rs 1,250 crore - Moneycontrol.com
Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore - The Economic Times
Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore - BusinessLine
Pfizer to cease Minipress XL operations, secures USD 13.9 million from US parent - Business Upturn
Novartis India Acquires Pfizer's Minipress for ₹1,250 Cr - Rediff MoneyWiz
Novartis India shares jump 4% on Rs 1,250 crore Pfizer trademarks acquisition - Business Today
Novartis India Buys Minipress Brand For ₹1,250 Crore, Pfizer To Stop Selling Hypertension Drug - Free Press Journal
Pfizer to Discontinue Minipress XL, Receives $13.9M - InvestyWise
Novartis India to acquire Minipress, Pfizer’s high blood pressure drug, for ₹1,250 crore - CNBC TV18
News by CNBC TV18 on TradingView, 2026-09-07 — cnbctv:e8e1f8f6f094b:0 - TradingView
Pfizer Limited To Stop Selling Minipress XL; To Receive ₹131.38 Crore Payment - Sahi
Novartis India acquires Pfizer Minipress IP rights for ₹1,250 crore - scanx.trade
Pfizer discontinues Minipress XL sales, to receive $13.9 million - scanx.trade
Pfizer Ltd to Discontinue Minipress XL; Receives Rs 131 Crore Compensation - Whalesbook
PFE Stock Quote Price and Forecast - CNN
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Pfizer Stock Price Forecast. Should You Buy PFE? - StockInvest.us
Pfizer (NYSE:PFE): Is Today’s Rally Hiding A Bigger Market Shift? - Kalkine Media
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.88%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):